Overview

Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs

Status:
RECRUITING

Trial end date:
2026-09-01

Target enrollment:

Participant gender:

Summary

This study will identify the potential benefits of regulating platelet activation with sotagliflozin compared to other FDA-approved drugs known to limit platelet activation.

Phase:

EARLY_PHASE1

Details

Lead Sponsor:

University of Michigan

Collaborator:

Lexicon Pharmaceuticals

Treatments:

(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol
apixaban